Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Illumina Inc (ILMN)

Laboratory Analytical Instruments

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

5200 ILLUMINA WAY
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/28/2000

Market Cap

20,706,610,500

Shares Outstanding

158,800,000

Weighted SO

158,800,000

Total Employees

N/A

Upcoming Earnings

08/06/2024

Similar Tickers

TMO --.--%

DHR --.--%

WAT --.--%

IDXX --.--%

A --.--%

EXAS --.--%

NTRA --.--%

CDNA --.--%

Beta

1.1490

Last Div

0.0000

Range

86.575874-166.8288

Chg

1.1850

Avg Vol

2790777

Mkt Cap

20706610500

Exch

NASDAQ

Country

US

Phone

858 202 4500

DCF Diff

67.0380

DCF

62.9526

Div Yield

0.0000

P/S

4.6752

EV Multiple

14.4267

P/FV

14.3925

Div Yield %

0.0000

P/E

-6.7896

PEG

-0.8849

Payout

0.0000

Current Ratio

1.1137

Quick Ratio

0.8596

Cash Ratio

0.4167

DSO

54.1443

DIO

121.7390

Op Cycle

175.8833

DPO

43.1837

CCC

132.6996

Gross Margin

0.6202

Op Margin

-0.0872

Pretax Margin

-0.6853

Net Margin

-0.6873

Eff Tax Rate

-0.0030

ROA

-0.5006

ROE

-0.6472

ROCE

-0.0997

NI/EBT

1.0030

EBT/EBIT

7.8627

EBIT/Rev

-0.0872

Debt Ratio

0.3790

D/E

1.6052

LT Debt/Cap

0.5092

Total Debt/Cap

0.6161

Int Coverage

128.6667

CF/Debt

0.2252

Equity Multi

4.2347

Rec Turnover

6.7412

Pay Turnover

8.4523

Inv Turnover

2.9982

FA Turnover

3.3578

Asset Turnover

0.7283

OCF/Share

3.2642

FCF/Share

2.2390

Cash/Share

6.2516

OCF/Sales

0.1172

FCF/OCF

0.6859

CF Coverage

0.2252

ST Coverage

0.6368

CapEx Coverage

3.1840

Div&CapEx Cov

3.1840

P/BV

14.3925

P/B

14.3925

P/S

4.6752

P/E

-6.7896

P/FCF

58.1646

P/OCF

39.8220

P/CF

39.8220

PEG

-0.8849

P/S

4.6752

EV Multiple

14.4267

P/FV

14.3925

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Feb 26, 01:30 Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™. GlobeNewswire Inc. Oct 04, 03:30 Onco-hematology Molecular Testing Market Size to Reach USD 1.5 billion by 2031 with a 12.5% CAGR, Boosted by Next-Generation Blood Cancer Diagnostics| Exclusive Report by Transparency Market Research, Inc. GlobeNewswire Inc. Sep 13, 00:30 Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights GlobeNewswire Inc. Aug 24, 18:35 Global Cancer Biomarkers Market to Surge from USD 22.78 Billion in 2023 to USD 82.66 Billion by 2033, Achieving a CAGR of 13.76% GlobeNewswire Inc. Jul 10, 05:10 Global Multiplex Assay Market Size to Hit $4.40 billion by - GlobeNewswire MarketWatch Jan 13, 10:48 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Jan 13, 10:48 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Jan 13, 10:48 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Jan 13, 10:48 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Jan 13, 10:48 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Jan 13, 10:48 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Jan 13, 10:48 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Jan 11, 14:29 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Jan 11, 14:29 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Jan 10, 18:07 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Jan 10, 15:34 Biden administration’s antitrust victories are much-needed wins for consumers MarketWatch Dec 30, 05:49 Here are the 20 worst-performing stocks among the S&P 500 in 2023 MarketWatch Dec 30, 05:49 Here are the 20 worst-performing stocks among the S&P 500 in 2023 MarketWatch Dec 29, 17:04 Here are the 20 worst-performing stocks among the S&P 500 in 2023 MarketWatch Dec 29, 11:18 Here are the 20 worst-performing stocks among the S&P 500 in 2023

Revenue Product Segmentation